ANXA2 and intrahepatic cholangiocarcinoma: Therefore, we suggest that bufalin inhibits CAMKK2 and affects ANXA2, subsequently impacting Wnt/β-catenin signaling pathway, promoting mitochondrial dysfunction, and inhibiting ICC proliferation and migration.